Press release from Companies
Publicerat: 2019-06-20 10:21:19
Today, on the 20th of June, 2019, the subscription period for Scandion Oncology A/S ("Scandion Oncology") rights issue begins. The subscription period runs until the 9th of July 2019. A fully subscribed issue of units will initially provide Scandion Oncology with approximately MSEK 29.3 and an additional approximately MSEK 12.4 (before issue costs) in a later stage if all consideration free warrants are exercised. Ahead of the rights issue, Scandion Oncology has received subscription commitments from, among others, senior executives and board members and also entered into agreements regarding top-down guarantee. In total, the subscription commitments and the top-down guarantees corresponds to approx. 89 percent of the inital issue volume. Prospectus, teaser and subscription forms are available through the websites of Scandion Oncology (www.scandiononcology.com) and Sedermera Fondkommission (www.sedermera.se). The investment documents are also available via Spotlight’s website (www.spotlightstockmarket.com). Subscription of units can be made by submitting a subscription form to Sedermera Fondkommission or through their website (via BankID).
Motivation for the rights issue To increase the commercial potential of the drug candidate SCO-101, Scandion Oncology’s new strategy is to run two clinical Phase II studies in metastatic, drug-resistant cancer patients. By initiating two Phase II clinical studies in parallel, i.e. colorectal and breast cancer, and with two different types of chemotherapy the Company will mitigate the risk by pursuing different cancer indications and increase the commercial value for SCO-101. Investor meetings In connection with the rights issue, Scandion Oncology will present the business and future plans at a number of investor events. See schedule below for details. Participation at the investor events is free of charge. Summary of the offering Summary of the consideration free warrants Financial advisor, issuing agent and legal advisor Sedermera Fondkommission is the financial advisor and issuing agent of Scandion Oncology in connection with the rights issue. Markets & Corporate Law acts as the legal advisor. For additional information regarding the rights issue, please contact: Sedermera Fondkommission Phone: +46 (0) 40-615 14 10 E-mail: info@sedermera.se For more information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com www.scandiononcology.com Scandion Oncology is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.
Date and time
Event
Place
Registration
June 24, 201917:30 – 19:30
Investor meeting in Stockholm
Scandic AnglaisHumlegårdsgatan 23102 44 Stockholm
Registration is made at www.sedermera.se
June 25, 201917:30 – 19.30
Investor meeting in Copenhagen
Copenhagen Admiral Hotel Toldbodgade 24-281253 Copenhagen
Registration is made at www.sedermera.se
June 26, 201911:30 – 13.00
Investor meeting in Malmo
Malmö BörshusSkeppsbron 2211 20 Malmo
Registration is made at www.sedermera.se
June 27, 201911:30 – 13.00
Investor meeting in Gothenburg
Elite Park Avenue HotelKungsportsavenyen 36411 36 Gothenburg
Registration is made at www.sedermera.se